文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

人脐带间充质干细胞(hUC-MSC PLEB001)治疗II-IV级激素难治性急性移植物抗宿主病:多中心、随机、双盲、安慰剂对照II期试验的研究方案

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial.
PubMed 文献 · Trials · 2023-05-03

本研究为多中心、随机、双盲、安慰剂对照II期试验方案,旨在评估人脐带间充质干细胞产品hUC-MSC PLEB001治疗II-IV级激素难治性急性移植物抗宿主病的疗效与安全性。共96例患者按1:1随机接受MSC或安慰剂治疗,每周两次、持续4周,同时按机构标准接受二线治疗;第28天达部分缓解者可再接受4周输注。

要点

  • 评估hUC-MSC PLEB001治疗II-IV级激素难治性aGVHD的疗效与安全性。
  • 96例患者按1:1随机接受MSC或安慰剂,每周两次、持续4周。
  • 第28天达部分缓解者可再接受每周两次、持续4周的输注。

核心结论

  • 本研究将评估MSC治疗一线激素治疗失败的II-IV级aGVHD患者的疗效与安全性。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照II期试验方案。
  • 共96例II-IV级激素难治性aGVHD患者按1:1随机接受MSC或安慰剂治疗。
  • MSC或安慰剂每周给药两次、持续4周,同时按机构标准接受二线治疗。
  • 第28天达部分缓解(PR)者可再接受每周两次、持续4周的输注。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic corticosteroid therapy failure is quite common in patients with newly diagnosed acute graft-versus-host disease (aGVHD). Growing evidence has suggested that mesenchymal stem cell (MSC) therapy could be a promising treatment option for aGVHD due to its distinctive immunomodulating functions. However, there is a lack of randomized well-controlled clinical trials. METHODS: This is a clinical trial protocol for a multicenter, randomized, double-blind, placebo-controlled phase II study. The aim of the trial is to evaluate the efficacy and safety of the administration of the human umbilical cord-derived MSC product hUC-MSC PLEB001 in patients with grade II-IV, steroid-refractory aGVHD. A total of 96 patients will be randomized 1:1 to receive MSC or placebo treatment twice per week for 4 weeks, in addition to second-line therapy according to institutional standards. Patients who achieve partial response (PR) at day 28 will be eligible to receive further infusions twice per week for an additional 4 weeks. DISCUSSION: This study will evaluate the efficacy and safety of MSC therapy in patients who have failed first-line steroid treatment for grade II-IV aGVHD. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR), ChiCTR2000035740. Registered on 16 August 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yang D, Hou X, Qian K, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial. Trials. 2023. PMID: 37138332. doi:10.1186/s13063-023-07305-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。